X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4228) 4228
Book Review (494) 494
Publication (190) 190
Conference Proceeding (36) 36
Book Chapter (17) 17
Newsletter (6) 6
Magazine Article (5) 5
Book / eBook (1) 1
Newspaper Article (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3598) 3598
humans (2915) 2915
deferoxamine (1817) 1817
deferoxamine - therapeutic use (1740) 1740
male (1705) 1705
female (1436) 1436
animals (1099) 1099
adult (1063) 1063
deferoxamine - pharmacology (810) 810
iron (809) 809
adolescent (759) 759
child (723) 723
iron chelating agents - therapeutic use (692) 692
iron - metabolism (689) 689
hematology (688) 688
desferrioxamine (672) 672
deferoxamine - administration & dosage (615) 615
middle aged (521) 521
abridged index medicus (502) 502
rats (499) 499
deferiprone (481) 481
thalassemia (446) 446
beta-thalassemia (441) 441
iron overload (434) 434
ferritins - blood (419) 419
child, preschool (409) 409
deferoxamine - adverse effects (398) 398
chelation therapy (383) 383
iron overload - drug therapy (375) 375
blood transfusion (358) 358
mice (343) 343
iron chelating agents - pharmacology (338) 338
transfusion reaction (328) 328
therapy (322) 322
beta-thalassemia - drug therapy (321) 321
biochemistry & molecular biology (315) 315
overload (296) 296
deferasirox (291) 291
pyridones - therapeutic use (287) 287
iron - blood (286) 286
oxidative stress (286) 286
thalassemia - drug therapy (281) 281
oncology (276) 276
pharmacology & pharmacy (260) 260
iron chelating agents - administration & dosage (251) 251
thalassemia - therapy (246) 246
aged (244) 244
thalassemia major (244) 244
pediatrics (243) 243
beta-thalassemia - complications (237) 237
ferritin (235) 235
iron overload - etiology (233) 233
chelation (225) 225
beta-thalassemia - therapy (223) 223
drug therapy, combination (216) 216
time factors (208) 208
survival (201) 201
medicine, general & internal (198) 198
disease models, animal (195) 195
iron chelating agents - adverse effects (195) 195
treatment outcome (195) 195
iron chelation (192) 192
siderophores - therapeutic use (179) 179
liver - metabolism (177) 177
chelation-therapy (175) 175
toxicity (174) 174
benzoates - therapeutic use (169) 169
disease (168) 168
dose-response relationship, drug (168) 168
triazoles - therapeutic use (168) 168
complications (167) 167
chelating agents - therapeutic use (165) 165
infant (163) 163
analysis (162) 162
iron - urine (161) 161
rats, sprague-dawley (160) 160
young adult (157) 157
magnetic resonance imaging (152) 152
renal dialysis - adverse effects (151) 151
health aspects (148) 148
administration, oral (147) 147
thalassemia - complications (146) 146
apoptosis (143) 143
cancer (142) 142
care and treatment (141) 141
neurosciences (141) 141
hemosiderosis - drug therapy (138) 138
anemia (137) 137
liver (134) 134
chelating agents (133) 133
transfusion (132) 132
beta-thalassemia major (130) 130
free radicals (129) 129
endocrinology & metabolism (128) 128
risk factors (127) 127
pyridones - administration & dosage (125) 125
cells, cultured (124) 124
expression (124) 124
toxicology (124) 124
children (123) 123
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3853) 3853
German (105) 105
French (87) 87
Italian (70) 70
Japanese (35) 35
Spanish (30) 30
Russian (20) 20
Polish (14) 14
Korean (9) 9
Czech (6) 6
Portuguese (5) 5
Romanian (4) 4
Chinese (3) 3
Dutch (3) 3
Hebrew (3) 3
Persian (2) 2
Serbian (2) 2
Swedish (2) 2
Arabic (1) 1
Bulgarian (1) 1
Croatian (1) 1
Danish (1) 1
Hungarian (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1989, ISBN 0702012971, Volume 2/no. 2., ix, p. 195-501.
Book
Journal Article
American Journal of Hematology, ISSN 0361-8609, 07/2018, Volume 93, Issue 7, pp. 943 - 952
Red blood cell transfusions have become standard of care for the prevention of life‐threatening anemia in patients with β‐thalassemia and sickle cell disease... 
OVERLOAD | MORTALITY | MULTICENTER | DEFEROXAMINE | MORBIDITY | RANDOMIZED CLINICAL-TRIAL | DESFERRIOXAMINE | HEMATOLOGY | DEFERIPRONE | INTERMEDIA | MAJOR PATIENTS | Cell survival | Cardiomyopathy | Diabetes mellitus | Liver | Ferritin | Systematic review | Thalassemia | Iron | Arthritis | Chelation therapy | Hypogonadism | Deferoxamine | Cirrhosis | Chelation | Sickle cell disease | Lead poisoning | Heart diseases | Index Medicus
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 2/2016, Volume 33, Issue 2, pp. 498 - 509
Journal Article
Haematologica, ISSN 0390-6078, 04/2010, Volume 95, Issue 4, pp. 557 - 566
Journal Article
Leukemia Research, ISSN 0145-2126, 2010, Volume 34, Issue 7, pp. 864 - 870
Journal Article
Circulation, ISSN 0009-7322, 04/2007, Volume 115, Issue 14, pp. 1876 - 1884
Background - Cardiac complications secondary to iron overload are the leading cause of death in beta-thalassemia major. Approximately two thirds of patients... 
Heart failure | Trials | Magnetic resonance imaging | Thalassemia | Deferiprone | Deferoxamine | Endothelium | OVERLOAD | SURVIVAL | endothelium | heart failure | DIAGNOSIS | magnetic resonance imaging | CARDIAC & CARDIOVASCULAR SYSTEMS | thalassemia | TREATED PATIENTS | DESFERRIOXAMINE | ENDOTHELIAL FUNCTION | deferiprone | deferoxamine | trials | CHELATION-THERAPY | TRANSFUSION | DISEASE | PERIPHERAL VASCULAR DISEASE | BETA-THALASSEMIA | HEMATOLOGY | Iron Overload - drug therapy | Myocardium - chemistry | Agranulocytosis - chemically induced | Humans | Deferoxamine - therapeutic use | Male | Chelation Therapy | beta-Thalassemia - complications | Deferoxamine - administration & dosage | Deferoxamine - adverse effects | Arthralgia - chemically induced | Heart Failure - prevention & control | Iron - analysis | Iron Overload - etiology | Pyridones - administration & dosage | Ferritins - blood | Adult | Female | Iron Chelating Agents - administration & dosage | Drug Therapy, Combination | Neutropenia - chemically induced | Iron Chelating Agents - therapeutic use | Double-Blind Method | Magnetic Resonance Spectroscopy | Endothelium, Vascular - physiopathology | Liver - chemistry | Iron Chelating Agents - adverse effects | Stroke Volume | beta-Thalassemia - drug therapy | Pyridones - therapeutic use | Gastrointestinal Diseases - chemically induced | Pyridones - adverse effects | Usage | Patient outcomes | Research | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2010, Volume 148, Issue 3, pp. 466 - 475
Summary Cardiac and endocrine disorders are common sequelae of iron overload in transfused thalassaemia patients. Combined chelation with desferrioxamine (DFO)... 
iron overload | thalassaemia | endocrinopathy | cardiomyopathy | combined chelation | Endocrinopathy | Iron overload | Thalassaemia | Combined chelation | Cardiomyopathy | CARDIOVASCULAR MAGNETIC-RESONANCE | HEART-FAILURE | INSULIN SENSITIVITY | TRANSFUSION-DEPENDENT THALASSEMIA | GLUCOSE-METABOLISM | MYOCARDIAL SIDEROSIS | SUBCLINICAL THYROID-DYSFUNCTION | BETA-THALASSEMIA | HEMATOLOGY | NORMOGLYCEMIC PATIENTS | COMBINED THERAPY | Follow-Up Studies | Iron Overload - drug therapy | Humans | Thyroxine - administration & dosage | Endocrine System Diseases - etiology | Deferoxamine - therapeutic use | Male | beta-Thalassemia - complications | Deferoxamine - adverse effects | Cardiomyopathies - etiology | Iron Overload - blood | Young Adult | Ferritins - blood | Adult | Female | Drug Therapy, Combination | Child | Endocrine System Diseases - drug therapy | Cardiomyopathies - drug therapy | Iron Chelating Agents - therapeutic use | beta-Thalassemia - therapy | Drug Administration Schedule | Liver - metabolism | Hypothyroidism - etiology | Iron Chelating Agents - adverse effects | Transfusion Reaction | Iron Overload - complications | Adolescent | Hypothyroidism - drug therapy | Pyridones - therapeutic use | Blood Glucose - metabolism | Pyridones - adverse effects | Testosterone | Complications and side effects | Glucose metabolism | Cardiac patients | Thyroxine | Ferritin | Isoflurophate | Iron | Glucose | Hypothyroidism | Dextrose | Index Medicus
Journal Article
Journal Article
European Journal of Haematology, ISSN 0902-4441, 06/2007, Volume 78, Issue 6, pp. 540 - 542
Transfusional iron overload in patients with chronic anemias can result in multiple organ failure. Experience in the management of iron overload in patients... 
iron overload | myelofibrosis | chelation | Iron overload | Chelation | Myelofibrosis | Primary Myelofibrosis - drug therapy | Iron Chelating Agents - therapeutic use | Anemia - drug therapy | Blood Transfusion | Humans | Deferoxamine - therapeutic use | Primary Myelofibrosis - therapy | Anemia | Care and treatment | Alternative medicine | Index Medicus
Journal Article